Technical Analysis for SNYNF - Sanofi

Grade Last Price % Change Price Change
A 109.0 -3.11% -3.5000
SNYNF closed down 3.11 percent on Monday, May 23, 2022, on 1 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Crossed Above 200 DMA Bullish -3.11%
Crossed Above 20 DMA Bullish -3.11%
Crossed Above 50 DMA Bullish -3.11%
MACD Bullish Signal Line Cross Bullish -3.11%
Narrow Range Bar Range Contraction -3.11%
Gapped Up Strength -3.11%
Oversold Stochastic Weakness -3.11%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 6.71%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Sanofi Description

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Chemistry Clinical Medicine Drugs Diabetes Arthritis Prostate Cancer Vaccines Cancers Urea Rheumatoid Arthritis Corona Monoclonal Antibody Health Care Products Dialysis Osteoarthritis Sclerosis Sterol Cholesterol Colorectal Cancer E Combination Insulin Influenza Multiple Sclerosis Dermatitis Axis Taxa Atopic Dermatitis Allergic Rhinitis Rhinitis Sanofi Mtr Insomnia Evotec Heparin Mucopolysaccharidosis Therapeutic Solutions Vix Atrial Fibrillation Consumer Health Care Products Gaucher Disease Insulin Glargine Meningitis Metastatic Colorectal Cancer Zara Acute Coronary Syndrome Docetaxel Fabry Disease Fibrillation Gaucher Lixisenatide Seasonal Allergic Rhinitis

Is SNYNF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 115.3706
52 Week Low 88.75
Average Volume 11,078
200-Day Moving Average 102.3274
50-Day Moving Average 104.8487
20-Day Moving Average 106.3772
10-Day Moving Average 104.1950
Average True Range 2.2639
RSI 56.90
ADX 15.46
+DI 57.7479
-DI 33.1079
Chandelier Exit (Long, 3 ATRs) 108.3783
Chandelier Exit (Short, 3 ATRs) 108.3717
Upper Bollinger Bands 114.1925
Lower Bollinger Band 98.5619
Percent B (%b) 0.67
BandWidth 14.6936
MACD Line -0.0022
MACD Signal Line -0.3040
MACD Histogram 0.3018
Fundamentals Value
Market Cap 136.8 Billion
Num Shares 1.26 Billion
EPS 3.88
Price-to-Earnings (P/E) Ratio 28.09
Price-to-Sales 2.78
Price-to-Book 1.65
PEG Ratio 3.18
Dividend 3.41
Dividend Yield 3.13%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 109.0000
Resistance 3 (R3) 109.0000 109.0000 109.0000
Resistance 2 (R2) 109.0000 109.0000 109.0000 109.0000
Resistance 1 (R1) 109.0000 109.0000 109.0000 109.0000 109.0000
Pivot Point 109.0000 109.0000 109.0000 109.0000 109.0000
Support 1 (S1) 109.0000 109.0000 109.0000 109.0000 109.0000
Support 2 (S2) 109.0000 109.0000 109.0000 109.0000
Support 3 (S3) 109.0000 109.0000 109.0000
Support 4 (S4) 109.0000